새로운 항응고제의 임상적 적용: 비판막성 심방세동 환자에서 뇌졸중의 예방을 위한 새로운 항응고제의 사용을 중심으로
Application of New Oral Anticoagulants: Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Only anticoagulation has been shown to reduce atrial fibrillation-related deaths. Vitamin K antagonists are difficult to use due totheir narrow therapeutic range, unpredictable response, requirement for frequent coagulation monitoring, frequent dose adjustment,slow onset-offset, and numerous drug-drug and drug-food interactions. New oral anticoagulants (NOACs), such as dabigatran,rivaroxaban, and apixaban have been developed and are available in Korea, and edoxaban was shown to be effective and safe, also. NOACs showed better pharmacodynamics with predictable serum concentrations and effects, and no requirement for coagulationmonitoring. These drugs have been shown to be more effective and safer than warfarin for prevention of stroke and systemicthromboembolism in patients with nonvalvular atrial fibrillation. Broad, appropriate, and aggressive use of NOACs would improvethe results of treatment in patients with nonvalvular atrial fibrillation in Korea.
Abstract
Only anticoagulation has been shown to reduce atrial fibrillation-related deaths. Vitamin K antagonists are difficult to use due totheir narrow therapeutic range, unpredictable response, requirement for frequent coagulation monitoring, frequent dose adjustment,slow onset-offset, and numerous drug-drug and drug-food interactions. New oral anticoagulants (NOACs), such as dabigatran,rivaroxaban, and apixaban have been developed and are available in Korea, and edoxaban was shown to be effective and safe, also. NOACs showed better pharmacodynamics with predictable serum concentrations and effects, and no requirement for coagulationmonitoring. These drugs have been shown to be more effective and safer than warfarin for prevention of stroke and systemicthromboembolism in patients with nonvalvular atrial fibrillation. Broad, appropriate, and aggressive use of NOACs would improvethe results of treatment in patients with nonvalvular atrial fibrillation in Korea.
참고문헌 (29)
- Stewart S, "Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew", Paisley study, 2001, pp.86, 516~521
- Go AS, "Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study", JAMA, 285, pp.2370~2375 (2001)
- Kirchhof P, "Outcome parameters for trials in atrial fibrillation: executive summary", Eur Heart J, 28, pp.2803~2817 (2007)
- Stewart S, "A populationbased study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew", Paisley Study, 2002, pp.113, 359~364
- Knecht S, "Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy", Eur Heart J, 29, pp.2125~2132 (2008)
- Thrall G, "Quality of life in patients with atrial fibrillation: a systematic review", Am J Med, 119, pp.448.e1~448.e19 (2006)
- Wyse DG, "A comparison of rate control and rhythm control in patients with atrial fibrillation", N Engl J Med, 347, pp.1825~1833 (2002)
- Van Gelder IC, "A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation", N Engl J Med, 347, pp.1834~1840 (2002)
- Roy D, "Rhythm control versus rate control for atrial fibrillation and heart failure", N Engl J Med, 358, pp.2667~2677 (2008)
- Van Gelder IC, "Lenient versus strict rate control in patients with atrial fibrillation", N Engl J Med, 362, pp.1363~1373 (2010)
- Hylek EM, "Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation", N Engl J Med, 349, pp.1019~1026 (2003)
- Hart RG, "Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation", Ann Intern Med, 146, pp.857~867 (2007)
- Sato H, "Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial", Stroke, 37, pp.447~451 (2006)
- Mant J, "Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial", Lancet, 370, pp.493~503 (2007)
- Rash A, "A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO)", Age Ageing, 36, pp.151~156 (2007)
- Connolly S, "Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial", Lancet, 367, pp.1903~1912 (2006)
- Camm AJ, "2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation: developed with the special contribution of the European Heart Rhythm Association", Europace, 14, pp.1385~1413 (2012)
- Skanes AC, "Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate", rhythm control, 2012, pp.28, 125~136
- Wann LS, "Management of patients with atrial fibrillation (compilation of 2006 ACCF", AHA, AHA, pp.HRS recommendations): a report of the American College of Cardiology, American Heart Association Task Force on practice guidelines[DOI]
- Friberg L, "Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation", Eur Heart J, 31, pp.967~975 (2010)
- Bendel SD, "Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation", Adv Ther, 28, pp.460~472 (2011)
- Kreutz R, "Pharmacodynamic and pharmacokinetic basics of rivaroxaban", Fundam Clin Pharmacol, 26, pp.27~32 (2012)
- Wong PC, "Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor", J Thromb Thrombolysis, 31, pp.478~492 (2011)
- Mendell J, "Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor", Am J Cardiovasc Drugs, 13, pp.331~342 (2013)
- Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361, pp.1139~1151 (2009)
- Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365, pp.883~891 (2011)
- Granger CB, "Apixaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 365, pp.981~992 (2011)
- Giugliano RP, "Edoxaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 369, pp.2093~2104 (2013)
- Miller CS, "Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation", Am J Cardiol, 110, pp.453~460 (2012)